MD  

April W. Armstrong


Presentations

Clinical Efficacy of Secukinumab vs Ustekinumab: 52-Week Treat-to-Target Endpoints in CLEAR, a Randomized Controlled Trial of Patients With Moderate to Severe Psoriasis 09 October 2019 00:00 - 00:00

Abstracts

Clinical Efficacy of Secukinumab vs Ustekinumab: 52-Week Treat-to-Target Endpoints in CLEAR, a Randomized Controlled Trial of Patients With Moderate to Severe Psoriasis Psoriasis More